Related Experiment Video
Updated: Dec 13, 2025

Cholesterol Efflux Assay
Published on: March 6, 2012
Hit or miss: the new cholesterol targets
Robert DuBroff1, Aseem Malhotra2, Michel de Lorgeril3
1Internal Medicine/Cardiology, University of New Mexico, Albuquerque, New Mexico, USA rjdabq@gmail.com.
Insights
New cholesterol guidelines recommend drug treatment for four high-risk groups. However, a review found no additional benefit, questioning the use of low-density lipoprotein cholesterol targets for cardiovascular disease prevention.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Current guidelines recommend cholesterol-lowering drug treatment for four moderate- to high-risk patient populations.
- These populations include those with a history of cardiovascular events, adult diabetics, individuals with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL, and those with a 10-year cardiovascular risk ≥7.5%.
Purpose of the Study:
- To evaluate the efficacy of achieving new cholesterol target levels in reducing cardiovascular events.
- To assess the validity of using LDL-C as a surrogate target for cardiovascular disease (CVD) prevention.
Main Methods:
- Systematic review of 35 randomized controlled trials (RCTs) investigating cholesterol-lowering treatments.
- Analysis focused on the benefits of achieving specific LDL-C target levels in the identified patient populations.
Main Results:
- Achieving the recommended cholesterol target levels did not confer any additional cardiovascular benefit across the studied trials.
- Current risk-based recommendations may lead to undertreatment of some high-risk individuals and overtreatment of low-risk individuals.
Conclusions:
- The effectiveness of current cholesterol-lowering treatment strategies based on achieving specific LDL-C targets is questionable.
- Rethinking the use of LDL-C as a sole surrogate marker for CVD prevention is warranted, given the negative results of numerous RCTs.
Abstract:
Drug treatment to reduce cholesterol to new target levels is now recommended in four moderate- to high-risk patient populations: patients who have already sustained a cardiovascular event, adult diabetic patients, individuals with low density lipoprotein cholesterol levels ≥190 mg/dL and individuals with an estimated 10-year cardiovascular risk ≥7.5%. Achieving these cholesterol target levels did not confer any additional benefit in a systematic review of 35 randomised controlled trials. Recommending cholesterol lowering treatment based on estimated cardiovascular risk fails to identify many high-risk patients and may lead to unnecessary treatment of low-risk individuals. The negative results of numerous cholesterol lowering randomised controlled trials call into question the validity of using low density lipoprotein cholesterol as a surrogate target for the prevention of cardiovascular disease.
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease IV: Preventive Measures

